BAY79-4620 (3ee9) Clinical Trials

TrialTitleStudy Record DetailPhaseSponsor/Colaborator
To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid TumorsNCT01028755Phase I
Bayer HealthCare AG (Berlin, Germany)
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid TumorsNCT01065623Phase I
Bayer HealthCare AG (Berlin, Germany)

Last Editorial Review: February 17, 2015